Výsledky vyhledávání - "Michael E. Luggen"

Akademický článek

Depression-, Pain-, and Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus

Autor: Nathalie E. Chalhoub, Michael E. Luggen

Publikováno v: International Journal of Rheumatology, Vol 2022 (2022)

Objectives. A significant number of patients with systemic lupus erythematosus (SLE) have depression, and many are untreated. We aim to assess the frequency of moderate to severe depression (MSD) in a multiethnic group of SLE patients with different

Externí odkaz: https://doaj.org/article/98def4e3310a4c6d89a45a5f13c5ee02

Zobrazit plný text záznamu

Plný text ve formátu HTML

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Autor: Eugen Feist, Saeed Fatenejad, Sergey Grishin, Elena Korneva, Michael E Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S Smolen, Roy M Fleischmann

Publikováno v: Modern Rheumatology Journal. 17:23-26

ObjectivesTo assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs).MethodsI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9da1b928747915d791bf834ce64c4d62
https://doi.org/10.14412/1996-7012-2023-2-23-36

Zobrazit plný text záznamu

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

Autor: Stephen J. Rozzo, Alan M. Mendelsohn, Alice B. Gottlieb, Siba P. Raychaudhuri, Proton Rahman, Saima Chohan, Philip J. Mease, Richard C Chou, Michael E. Luggen, Ferran J Garcia Fructuoso

Publikováno v: Annals of the Rheumatic Diseases

ObjectivesTo evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA).MethodsIn this randomised, double-blind, placebo-controlled, phase IIb study, patients with active Ps

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45699aa413018d161e9029b076da7135
https://doi.org/10.1136/annrheumdis-2020-219014

Zobrazit plný text záznamu

P136 Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-α inhibitor therapy

Autor: Michael E. Luggen, Evgeniy L Nasonov, Sergey Grishin, Eugen Feist, Elena Korneva, Saeed Fatenejad, Mikhail Samsonov

Publikováno v: Rheumatology. 60

Background/Aims Olokizumab (OKZ) is a new humanised monoclonal antibody targeting IL-6. Here we present the results of the phase III study of OKZ in anti-TNF-IR patients. Methods Patients with moderately to severely active RA who had previously faile

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::077e50bf22933e6c1b2ffb282ddad694
https://doi.org/10.1093/rheumatology/keab247.132

Zobrazit plný text záznamu

Screening for cognitive dysfunction in systemic lupus erythematosus: the Montreal Cognitive Assessment Questionnaire and the Informant Questionnaire on Cognitive Decline in the Elderly

Autor: N E Chalhoub, Michael E. Luggen

Publikováno v: Lupus. 28:51-58

Background Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). Traditional neuropsychological testing and the Automated Neuropsychologic Assessment Metrics (ANAM) have been used t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::871a1752a6acf0d63a112f89de803e5c
https://doi.org/10.1177/0961203318815299

Zobrazit plný text záznamu

OP0230 EFFICACY AND SAFETY OF TILDRAKIZUMAB, A HIGH-AFFINITY ANTI–INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 2B STUDY

Autor: Alan M. Mendelsohn, Richard C Chou, Michael E. Luggen, Alice B. Gottlieb, P. J. Mease, Saima Chohan, Ana Maria Orbai, Proton Rahman, Siba P. Raychaudhuri, F. J. García Fructuoso, Stephen J. Rozzo

Publikováno v: Annals of the Rheumatic Diseases. 79:145-146

Background:Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate to severe plaque psoriasis and is under investigation for treatment of psoriatic arthritis (PsA).1Objectives:To evaluate effic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2906765078cb825a40410abfdfa2e55
https://doi.org/10.1136/annrheumdis-2020-eular.3908

Zobrazit plný text záznamu

Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction

Autor: Philip H. Iffland, Bin Zhang, Damir Janigro, Michael E. Luggen, Gaurav Gulati

Publikováno v: Clinical Rheumatology. 35:2989-2997

Cognitive dysfunction (CD) is one of the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). In animal models, antibodies to NR2 subunit of N-methyl d-aspartate receptor (anti-NR2) cause memory impairment, but only with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07396ba1b3fe7a24c85781abd84f6488
https://doi.org/10.1007/s10067-016-3339-1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání